We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cumberland Pharmaceutical Inc | NASDAQ:CPIX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.07 | 4.64% | 1.58 | 1.45 | 1.85 | 1.6499 | 1.575 | 1.58 | 9,703 | 22:33:35 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
KAZIMI A J |
2. Issuer Name
and
Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__ X __ Director __ X __ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) Chairman and CEO |
2525 WEST END AVE., SUITE 950 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
NASHVILLE, TN 37203 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 4/12/2019 | P | 99 (1) | A | $6.32 | 5760899 | D | |||
Common Stock | 4/17/2019 | P | 81 (1) | A | $6.21 | 5760980 | D | |||
Common Stock | 4/24/2019 | P | 32 (1) | A | $6.04 | 5761012 | D | |||
Common Stock | 4/25/2019 | P | 24 (1) | A | $6.17 | 5761036 | D | |||
Common Stock | 4/26/2019 | P | 14 (1) | A | $6.32 | 5761050 | D | |||
Common Stock | 4/30/2019 | P | 27 (1) | A | $6.37 | 5761077 | D | |||
Common Stock | 5/2/2019 | P | 73 (1) | A | $5.61 | 5761150 | D | |||
Common Stock | 5/6/2019 | P | 42 (1) | A | $6.29 | 5761192 | D | |||
Common Stock | 5/7/2019 | P | 23 (1) | A | $6.07 | 5761215 | D | |||
Common Stock | 5/8/2019 | P | 58 (1) | A | $6.35 | 5761273 | D | |||
Common Stock | 5/10/2019 | P | 57 (1) | A | $6.01 | 5761330 | D | |||
Common Stock | 5/14/2019 | P | 36 (1) | A | $5.62 | 5761366 | D | |||
Common Stock | 5/17/2019 | P | 106 (1) | A | $6.25 | 5761472 | D | |||
Common Stock | 5/20/2019 | P | 60 (1) | A | $6.89 | 5761532 | D | |||
Common Stock | 5/21/2019 | P | 60 (1) | A | $6.71 | 5761592 | D | |||
Common Stock | 5/22/2019 | P | 60 (1) | A | $6.58 | 5761652 | D | |||
Common Stock | 5/23/2019 | P | 60 (1) | A | $6.53 | 5761712 | D | |||
Common Stock | 5/24/2019 | P | 60 (1) | A | $6.67 | 5761772 | D | |||
Common Stock | 5/28/2019 | P | 60 (1) | A | $6.65 | 5761832 | D | |||
Common Stock | 5/29/2019 | P | 60 (1) | A | $6.53 | 5761892 | D | |||
Common Stock | 5/30/2019 | P | 60 (1) | A | $6.58 | 5761952 | D | |||
Common Stock | 5/31/2019 | P | 60 (1) | A | $6.57 | 5762012 | D | |||
Common Stock | 6/3/2019 | P | 60 (1) | A | $6.49 | 5762072 | D | |||
Common Stock | 6/4/2019 | P | 60 (1) | A | $6.60 | 5762132 | D | |||
Common Stock | 6/5/2019 | P | 50 (1) | A | $6.67 | 5762182 | D | |||
Common Stock | 6/6/2019 | P | 60 (1) | A | $6.38 | 5762242 | D | |||
Common Stock | 6/7/2019 | P | 60 (1) | A | $6.07 | 5762302 | D | |||
Common Stock | 6/10/2019 | P | 60 (1) | A | $6.09 | 5762362 | D | |||
Common Stock | 6/11/2019 | P | 60 (1) | A | $6.32 | 5762422 | D | |||
Common Stock | 6/12/2019 | P | 60 (1) | A | $6.29 | 5762482 | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: | |
(1) | The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
KAZIMI A J
2525 WEST END AVE. SUITE 950 NASHVILLE, TN 37203 |
X | X | Chairman and CEO |
|
Signatures
|
||
A.J. Kazimi by /s/ Michael Bonner as attorney-in-fact | 6/14/2019 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Cumberland Pharmaceutical Chart |
1 Month Cumberland Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions